HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 216 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is 0.44 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $842,272 | +108.5% | 22,049 | +96.9% | 0.00% | – |
| Q2 2023 | $403,984 | -60.7% | 11,200 | -58.3% | 0.00% | -100.0% |
| Q1 2023 | $1,026,776 | -40.6% | 26,886 | -11.5% | 0.00% | -50.0% |
| Q4 2022 | $1,728,907 | +61.9% | 30,385 | +12.5% | 0.00% | +100.0% |
| Q3 2022 | $1,068,000 | +0.8% | 27,017 | +12.1% | 0.00% | 0.0% |
| Q2 2022 | $1,060,000 | -23.4% | 24,100 | -30.5% | 0.00% | 0.0% |
| Q1 2022 | $1,383,000 | -84.9% | 34,673 | -84.8% | 0.00% | -87.5% |
| Q4 2021 | $9,172,000 | -0.4% | 228,107 | +0.8% | 0.01% | 0.0% |
| Q3 2021 | $9,206,000 | -53.7% | 226,311 | -48.3% | 0.01% | -52.9% |
| Q2 2021 | $19,862,000 | -45.1% | 437,398 | -49.6% | 0.02% | -51.4% |
| Q1 2021 | $36,207,000 | -34.5% | 868,463 | -32.9% | 0.04% | -28.6% |
| Q4 2020 | $55,276,000 | -11.4% | 1,294,204 | -45.5% | 0.05% | -23.4% |
| Q3 2020 | $62,360,000 | +10.7% | 2,372,913 | +12.9% | 0.06% | -4.5% |
| Q2 2020 | $56,325,000 | +64.5% | 2,100,886 | +10.4% | 0.07% | +26.4% |
| Q1 2020 | $34,245,000 | -6.9% | 1,903,593 | -8.3% | 0.05% | +26.2% |
| Q4 2019 | $36,794,000 | +332.4% | 2,075,223 | +278.2% | 0.04% | +320.0% |
| Q3 2019 | $8,510,000 | -10.5% | 548,665 | -0.9% | 0.01% | -16.7% |
| Q2 2019 | $9,507,000 | +84.5% | 553,386 | +72.9% | 0.01% | +71.4% |
| Q1 2019 | $5,152,000 | -12.6% | 319,986 | -20.6% | 0.01% | -12.5% |
| Q4 2018 | $5,894,000 | -12.4% | 402,884 | +8.8% | 0.01% | 0.0% |
| Q3 2018 | $6,725,000 | +98.6% | 370,163 | +84.4% | 0.01% | +100.0% |
| Q2 2018 | $3,386,000 | +99.4% | 200,738 | +131.6% | 0.00% | +100.0% |
| Q1 2018 | $1,698,000 | -75.5% | 86,684 | -74.7% | 0.00% | -80.0% |
| Q4 2017 | $6,943,000 | +5.9% | 342,736 | -9.2% | 0.01% | 0.0% |
| Q3 2017 | $6,555,000 | +4516.2% | 377,356 | +3313.8% | 0.01% | – |
| Q2 2017 | $142,000 | +42.0% | 11,054 | +9.3% | 0.00% | – |
| Q4 2016 | $100,000 | -88.2% | 10,112 | -85.6% | 0.00% | -100.0% |
| Q3 2016 | $850,000 | -38.0% | 70,391 | -11.0% | 0.00% | -50.0% |
| Q4 2015 | $1,371,000 | +1.1% | 79,095 | -21.7% | 0.00% | 0.0% |
| Q3 2015 | $1,356,000 | -63.5% | 100,985 | -38.6% | 0.00% | -66.7% |
| Q2 2015 | $3,714,000 | +139.6% | 164,480 | +51.6% | 0.01% | +200.0% |
| Q1 2015 | $1,550,000 | +320.1% | 108,511 | +183.9% | 0.00% | – |
| Q4 2014 | $369,000 | +77.4% | 38,220 | +67.5% | 0.00% | – |
| Q3 2014 | $208,000 | -61.9% | 22,820 | -58.7% | 0.00% | -100.0% |
| Q2 2014 | $546,000 | +259.2% | 55,300 | +360.8% | 0.00% | – |
| Q1 2014 | $152,000 | – | 12,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |